Breast-cancer-associated gene 1 (BRCA1) is highly expressed in thymus and spleen. In this paper, we have studied lymphocyte development and tumorigenesis in mice carrying mutations in Brca1 and p53. We show that the deletion of Brca1 exon 11 (Brca1-D11), which disrupts the full-length isoform, but not the short isoform of Brca1, does not interfere with lymphocyte development. This is true irrespective of p53 status, that is, whether it is wild type, heterozygous or homozygous for a null mutation. These data suggest that the expression of Brca1 short isoform alone is enough to maintain normal development of lymphocytes. However, it cannot suppress tumorigenesis as about 30% of Brca1
Introduction
Women heterozygous for germ line mutation in the tumor-suppressor gene BRCA1 have an estimated 50-80% lifetime risk of developing breast or ovarian cancers (Easton et al., 1995; Ford et al., 1998) . The BRCA1 gene encodes a nuclear protein composed of 1863 amino acids in humans (Miki et al., 1994) and 1812 in mice (Bennett et al., 1995; Lane et al., 1995; Marquis et al., 1995; Sharan et al., 1995) . A smaller isoform (BRCA1-D11), generated by alternative splicing of BRCA1 exon 11, is observed in human (Thakur et al., 1997; Wilson et al., 1997) and murine cells (Xu et al., 1999b; Bachelier et al., 2000) . Both isoforms are cell cycle regulated, with the highest levels of expression during the G1/S transition (Chen et al., 1996; Huber et al., 2001) . After irradiation, BRCA1 is phosphorylated by ATM (Cortez et al., 1999; Gatei et al., 2000) , ATR (Tibbetts et al., 2000; Gatei et al., 2001) , Cds1/ CHK2 (Lee et al., 2000) and associates with Rad51 or Rad50 (Scully et al., 1997; Chen et al., 1999; Zhong et al., 1999; Huber et al., 2001) . Both Rad50 and Rad51 are involved in DNA damage repair by homologous recombination, and Rad50 also plays a role in the nonhomologous end joining pathway (Moore and Haber, 1996; Huang and Dynan, 2002) .
In mouse embryos, Brca1 is highly expressed in rapidly proliferating and differentiating cells (Lane et al., 1995) . The complete knockout of the Brca1 gene is lethal shortly after gastrulation (Hakem et al., 1996; Liu et al., 1996; Ludwig et al., 1997; Shen et al., 1998) . Mutant embryos exhibited growth arrest and increased apoptosis, perhaps because of an activation of a p53-mediated cell cycle checkpoint, as the embryonic lethality triggered by Brca1-null mutations was slightly delayed in a p53 À/À background (Hakem et al., 1997; Ludwig et al., 1997; Shen et al., 1998) . On the other hand, most of the mutant embryos that are homozygous for a germline deletion of Brca1 exon 11 died later in gestation, and the lethality could be overcome when one or both p53 alleles were mutated (Brca1
p53 À/À mice) (Xu et al., 2001) . Murine embryonic fibroblasts (MEFs) derived from Brca1 D11/D11 mice displayed pleiotropic phenotypes including increased apoptosis, genomic instability, centrosome amplification and a loss of the G2/M checkpoint (Xu et al., 1999b) . BRCA1 mutant cells have also been shown to be defective in several pathways of DNA repair: nuclear excision repair (Hartman and Ford, 2002) , transcription-coupled repair of oxydative DNA damage (Gowen et al., 1998; Abbott et al., 1999) , homologous recombinational repair (Moynahan et al., 1999 (Moynahan et al., , 2001 Snouwaert et al., 1999) and nonhomologous end joining (Baldeyron et al., 2002; Zhong et al., 2002a, b) .
Brca1 has recently been implicated in lymphogenesis and lymphoma formation. A conditional knockout of Brca1 exons 5 and 6 in the T-cell lineage (tBrca1 À/À mice) revealed that Brca1 is required for T-cell lineage development (Mak et al., 2000 ) revealed that about 30% of homozygous mice developed lymphoma (Ludwig et al., 2001) . Our study on Brca1
female mice also indicated that the impairment of Brca1 function could result in lymphoma formation (Xu et al., 2001) . Despite these efforts, the mechanisms underlying Brca1-associated lymphoma remain unclear. To address this, we decide to use the Brca1 D11/D11 p53 +/À mice, which survive to adulthood owing to the combined effect of p53 haploinsufficiency and expression of the Brca1-D11 isoform (Xu et al., 2001) . Since the BRCA1-D11 isoform is also expressed in thymus and spleen (Miki et al., 1994; Lane et al., 1995) , we hypothesize that this isoform may play a role in lymphogenesis and lymphoma formation. Moreover, in tBrca1 À/À mice, the conditional knockout is only performed in T-cell lineage using Lck-Cre (Mak et al., 2000) , while Brca1
+/À mice contain the Brca1 exon 11 deletion in all tissues/organs. Therefore, we would like to determine if this mutation could affect B-cell lineage development.
In this paper, we have tested this hypothesis and studied interplay between Brca1 and p53 during B-cell and T-cell differentiation, proliferation, apoptosis and tumorigenesis in Brca1 D11/D11 mice carrying various combinations of a p53-null mutation.
Results

Brca1
D11/D11 mice exhibit normal T-and B-cell lineage development irrespective of their p53 status
p53 À/À mice survive to adulthood (Xu et al., 2001) . To study the potential effects of Brca1-D11 deficiency on lymphocyte development in these mice, we performed fluorescenceactivated cell sorting (FACS) analysis on lymphocytes issued from thymus and spleen. We observed no differences in the total number of thymocytes between mutant and control mice ( Figure 1a (Figure 1b) . The distribution of both B and T lymphocytes in spleen was assessed by FACS using the B220 (CD45R) and Thy-1 (CD90) markers, respectively, and was found to be similar in Brca1
D11/D11 p53 À/À and control mice ( Figure 1c ). Overall, these results indicate that T-cell lineage development is 
CD8
+ T-cells and immunoglobulin production by B cells suggest that V(D)J recombination is effective in these mice (Figure 1b and not shown).
It was shown that conditional deletion of Brca1 exons 5 and 6 in T cells (tBrca1
) resulted in defective T-cell lineage development, which could be rescued by the loss of p53 (Mak et al., 2000) . Thus, the normal T-and B-cell lineage development in Brca1
+/À and Brca1 D11/ D11 p53 À/À mice could be because of the decrease or loss of p53 functions. On the other hand, differing from tBrca1 À/À mice, the Brca1 D11/D11 mice, irrespective of their p53 status, still express the shorter isoform of Brca1, which is a natural product generated by alternative splicing of exons 10-12 (Xu et al., 1999b) , in their lymphoid tissues and the derived cell lines (Figure 2a, b) . Therefore, it is possible that the presence of this form supported T-and B-cell development in the absence of Brca1 full-length form. We have shown previously that small number (o2%) of Brca1 D11/D11 p53 +/+ mice survived to adulthood (Xu et al., 2001 ). The status of T and B cells in these mice could provide a key to distinguish these possibilities. Therefore, we analysed the Brca1 D11/D11 p53 +/+ mice and found that their lymphogenesis was indistinguishable with those of wild-type controls (Figure 1a -c). Thus, unlike the tBrca1 À/À mice, Brca1 D11/D11 mice have a normal development of T-and B-cell lineages irrespective of their p53 status.
T-cell, but not B-cell, lymphomas found in mice carrying mutations in Brca1 and p53
Although Brca1 D11/D11 p53 +/À mice have a normal development of T-and B-cell lineages, many of them developed lymphomas. The affected mutant mice were usually sick, suffered breath difficulty and died shortly after appearance of the symptom. Upon autopsy, most of them exhibited enlarged thymus (Figure 3a) , which occupy most space in the thoracic cage and may be a primary reason for the short breath exhibited by the sick animals. Histologic analysis on the enlarged thymuses detected neoplastic infiltration with large anaplastic cells, with large nuclei, prominent nucleoli, clumped chromatin, scant cytoplasm and high mitotic rate ( Figure 3b and not shown). To determine the nature of these tumors, that is, whether they are T-cell or B-cell lymphomas, we performed immunohistochemical staining using antibodies for T cells (CD3) and B cells (B220). Our results indicated that all the lymphomas analysed (n ¼ 14) stained positive for CD3 (Figure 3d ), but not for B220 (Figure 3e ). Several mutant mice also displayed enlarged spleen (not shown). Our analysis indicated that enlarged spleens were positive for CD3 (Figure 3f ), suggesting that the enlargement is perhaps caused by the penetration and accumulation of T cells. Thus, despite high levels of Brca1 expression in spleen, no B-cell lymphomas were observed. This result suggests that the absence of Brca1 exon 11 in a p53 +/À background predisposes mice to T lymphomas but not B lymphomas.
Loss of Brca1 and p53 synergistically promotes T-lymphoma formation
Next, we determined the status of the wild-type p53 allele in the lymphomas that developed in Brca1
+/À mice. Southern blot analysis demonstrated that all the primary lymphomas (n ¼ 4, Figure 4a ) and cell lines (n ¼ 5, Figure 4b ) derived from the tumors had lost their wild-type allele of p53. These data suggest that the inactivation of p53 is required for lymphoma formation in Brca1 D11/D11 p53 +/À mice. To provide a definitive proof for this, we compared the profiles of lymphoma formation between Brca1
mice. If complete loss of the wild-type p53 allele is required for lymphoma formation, tumorigenesis should be accelerated in Brca1
p53 À/À mice as the remaining wild-type allele of p53 has been deleted. On the other hand, if p53 loss was a secondary consequence, then the tumor formation rate would remain unchanged between these two groups of mice. As shown in Figure 4c , about 27 (18/66) of Brca1 D11/D11 p53 +/À mice developed lymphomas in 12 to 28-week-old mice, whereas none of the p53 +/À control mice developed lymphoma during the same period of the time. The deletion of the remaining wild-type allele of p53 (Brca1
) dramatically accelerated T-cell lymphoma formation as reflected by both increased tumor frequency and shortened time of tumor initiation. Since the loss of p53 function also causes lymphoma formation (Donehower et al., 1992; Jacks et al., 1994; Brodie et al., 2001a) , we included p53 À/À mice as a control and found that the frequency of lymphoma in p53 À/À mice was significantly lower than that exhibited by Brca1
À/À mice ( Figure 4c ). These observations indicate that the enhanced lymphoma formation is because of the joint actions of the loss of Brca1 and p53. In addition, we have also followed tumorigenesis of seven Brca1 D11/D11 p53 +/+ mice (three females and four males) that survived over 1 year. We found that none of them developed lymphoma although two females developed mammary tumors and the remaining five died without an apparent reason. This is consistent with the view that Brca1-associated lymphoma formation requires loss of p53 function, as the Brca1
+/+ mice contain two p53 wild-type alleles that require an extra step for their deletion compared with Brca1 D11/D11 p53 +/À mice. Since all normal Brca1 D11/D11 cells should contain the 3.9 kb transcripts, next, we were interested to determine if this form needs to be eliminated for lymphoma development. Northern blot revealed that all the primary tumors and cell lines examined retained this form of Brca1 (Figure 2b ), suggesting that its presence does not repress tumor formation; therefore, it does not have to be deleted.
Absence of Brca1 exon 11 does not affect T-cell proliferation, however increases g-irradiation-induced apoptosis, which is attenuated by the loss of p53
To explore molecular and cellular alterations associated with lymphoma development, we next addressed whether the lack of Brca1 full-length isoform would affect cell proliferation and apoptosis. Our data indicated that the proliferation of thymocytes was similar in mutant and control mice as determined by immunohistochemical staining using an antibody to BrdU (Figure 5a, b) . Analysis of cell proliferation in spleen using the same approaches revealed similar results (not shown). These observations indicate that the absence of Brca1 full-length isoform does not affect the proliferation of lymphocytes.
We next determined the level of apoptosis in thymocytes before and after g-irradiation treatment using FACS analysis. In wild-type mice, about 2% of thymocytes underwent apoptosis as revealed by sub-2n content. Upon g-irradiation, the percentages of apoptotic thymocytes increased to 35% (Figure 5f ). In Brca1 D11/ D11 p53 +/+ mice, although the basal level of apoptosis was similar to that of control cells, a dramatic increase of apoptosis (66%) was observed after g-irradiation (Figure 5g ). This observation indicates that the Brca1 exon 11 deletion sensitizes mutant lymphocytes to girradiation-induced apoptosis. Our further analysis revealed that p53 played a critical role in this process as the loss of one copy of p53 decreased (Figure 5h , i) and further deletion of the remaining wild type p53 allele completely blocked (Figure 5j , k) the g-irradiation induced apoptosis.
Since FACS analysis only detects DNA contents of cells, we next performed TUNEL assay in order to provide an independent confirmation. Our analysis revealed similar high rates of apoptosis in Brca1 mutant lymphocytes upon g-irradiation and similar attenuation of apoptosis by the decreased dose of p53 (Figure 5c-e) . Altogether, these observations suggest that the absence of Brca1 full-length isoform decreases the ability of T cells to repair the DNA damages caused by g-irradiation, which triggers p53-dependent apoptosis. This may account for the development of lymphomas in Brca1 D11/ D11 mice when their p53 activities are decreased (Brca1
The development of lymphomas in Brca1
D11/D11 p53 +/À and Brca1
is associated with genetic instability
Consistent with a role for Brca1 in DNA repair, most lymphoma cell lines established from Brca1 +/À mice used in this study also carry conditional knockout of Brca1 (Brca1
Co/Co MMTV-Cre) in their mammary glands (Xu et al., 1999a) . They were used here as a control simply indicating that p53 heterozygous mutation does not cause lymphoma during this period of time. p53 À/À also developed several other types of tumors as shown previously (Brodie et al., 2001a) . Brca1 p53 À/À (e) mice irradiated with a dose of 0 or 10 Gy (g-k) FACS analysis on thymocytes from mice carrying various combinations of Brca1 and p53 mutations labeled with propidium iodide after receiving a dose of 0 or 10 Gy of g-irradiation. The percentages of cells in sub-2n, 2n and 4n phases are indicated Tumorigenesis in BRCA1 and P53 mutant mice R Bachelier et al stability (Zhong et al., 1999) . In order to determine whether the loss of telomere was responsible for the genomic instability in Brca1 mutant lymphoma cells, we performed Q-fish and found that the telomeres appeared normal (Figure 6c ), excluding telomere shortening as a cause for Brca1-associated genomic alterations.
Discussion
We have studied lymphocyte development, tumorigenesis and genetic interplay between Brca1 and p53 in the Brca1 D11/D11 , Brca1
p53 +/À and Brca1
mice. There are several novel findings that can be concluded from this study. First, our data indicate that Brca1-D11 isoform is sufficient to support normal development of both B-and T-cell lineages; however, it cannot repress lymphoma formation. Second, we show that lymphomas in these mice are derived from T cells, but not B cells, despite the high expression of Brca1 in the spleen. Finally, we demonstrate that lymphomagenesis is dramatically accelerated by a p53-null mutation at expenses of genetic stability. It has been previously reported that mice with a thymus-specific deletion of Brca1 exons 5 and 6 (tBrca1 mice, mice carrying a germline deletion of Brca1 exon 11 had a normal distribution of thymocyte subpopulations irrespective to their p53 status. They also displayed normal levels of proliferation and exhibited no elevation in background apoptosis. One intrinsic difference between tBrca1 À/À and Brca1 D11/D11 mice is that the former is a candidate null mutation and the latter still expresses the Brca1-D11 isoform. This isoform contains a number of functional domains, such as RING domain (Meza et al., 1999) and BRCT (Bork et al., 1997; Callebaut and Mornon, 1997) , and therefore, it is expected to be able to bind some of the BRCA1 interacting proteins (Deng and Brodie, 2000) and may even maintain some transactivation activity. While this is still controversial (Bochar et al., 2000; Chai et al., 1999; Lu and Arrick, 2000) and needs to be further tested, the normal contents of both T-and B-cell lineages indicate that the presence of the Brca1-D11 isoform is sufficient to support the development of lymphocytes in the absence of the full-length form. Of note, our earlier studies demonstrated that the presence of the Brca1-D11 isoform could not maintain normal growth of Brca1 D11/D11 embryos and mutant MEF cells, as the mutant embryos died during gestation and mutant cells exhibited profound growth defects (Xu et al., 1999b (Xu et al., , 2001 ). These observations suggest that the functional importance of Brca1 isoforms may vary among different tissues.
Although the Brca1 D11/D11 thymocytes have a basal level of apoptosis comparable to wild-type thymocytes, they exhibited dramatically increased apoptosis upon girradiation, which is consistent with the view that Brca1 plays an essential role in DNA-damage repair (Brodie and Deng, 2001; Venkitaraman, 2002) . Brca1 has been found to form complexes with Rad51-Brca2 (Scully et al., 1997; Chen et al., 1999; Zhong et al., 1999; Huber et al., 2001 ) and Rad50-Mre11-Nbs1 (Zhong et al., 1999) , respectively. Both complexes were known to play roles in DNA-damage repair by homologous recombination (reviewed in Thompson and Schild, 2001) . Of note, the interaction sites of Brca1 with RAD50 and RAD51 are located within exon 11 (Scully et al., 1997; Zhong et al., 1999) . Therefore, the short isoform, which lacks exon 11, should not form complexes with RAD50, RAD51 and their associated proteins. Consistently, it was shown recently that Brca1 D11/D11 MEF cells could not form RAD51 nuclear foci upon g-irradiation (Huber et al., 2001) . We demonstrated here that lymphoma cell lines established from Brca1
+/À mice were characterized by increased aneuploidy, a higher percentage of double minute chromosomes and chromosomal abnormalities. These abnormalities may account for the dramatically elevated apoptosis observed in the Brca1 D11/ D11 thymocytes after irradiation. Altogether, these observations suggest that, while sufficient for supporting normal development of lymphocytes, the Brca1-D11 isoform plays very little role in repairing DNA damages.
Thus, the accumulation of DNA damage and genetic instability associated with the absence of Brca1 full-length isoform could be a mechanism underlying the lymphomagenesis in the Brca1 mutant mice. Lymphocytes undergo quick cell proliferation, death and fast turnover, and therefore, require extensive DNA-damage repair function. Brca1 and its interacting proteins play an important role in maintaining genetic stability and, therefore, support normal growth and development of lymphocytes. We showed that the absence of Brca1 fulllength isoform does not prevent lymphocyte proliferation. Thus, the proliferation of T cells without a proper function of Brca1 allows the accumulation of mutations such as those generated by illegitimate recombination and translocation, leading to the activation of protooncogenes and tumorigenesis. Consistently, mutations of many genes involved in DNA-damage repair are associated with the development of hematologic tumors (Elliott and Jasin, 2002) . Many of them have been known to either interact with BRCA1 or to be involved in BRCA1 transactivation pathways. These include ATM (Barlow et al., 1996) , BRCA2 (Connor et al., 1997) , MSH2 (Wang et al., 2001) , MSH6 (Edelmann et al., 1997) , p53 (Donehower et al., 1992) , BLM (Gretzula et al., 1987; Luo et al., 2000) and Fanconi Anemia proteins (Garcia-Higuera et al., 2001) .
Of note, both mouse and human BRCA1 mutation heterozygous carriers do not develop lymphoma. As human homozygous mutation carriers are not viable (Kuschel et al., 2001) , it is not possible to predict whether they would develop lymphoma if they could survive to adulthood. Therefore, our work could only suggest that BRCA1 has a potential to repress lymphoma development. Nonetheless, our work reveals an important role of Brca1 in maintaining genetic stability, which is essential for repressing tumorigenesis in general (Khanna and Jackson, 2001; Bernstein et al., 2002) . Furthermore, our study revealed a significant interplay between Brca1 and p53 in thymocyte development and thymic lymphoma formation. First, we demonstrate that g-irradiation-induced apoptosis in Brca1 D11/D11 thymocytes is primarily because of the activation of p53, as p53 haploid loss attenuates, and the absence of p53 completely blocks the killing. We also demonstrated that complete inactivation of p53 is required for Brca1-associated tumorigenesis in thymus, as all examined tumors from Brca1 
p53
À/À lymphoma cell lines exhibited more extensive chromosome alterations than cell lines derived from p53 À/À lymphoma. Altogether, our data illustrate a mechanism underlying Brca1-associated formation. The absence of Brca1 full-length isoform causes accumulation of DNA damage and genetic instability, which triggers p53-mediated apoptosis that eliminates the mutant cells and prevents tumor formation. On the other hand, the loss of p53 attenuates apoptosis, allowing cells with mutations to survive, eventually leading to lymphoma formation.
Materials and methods
Mice, tissue histology, BrdU labeling and apoptosis assay Brca1 (Xu et al., 2001) and Trp53 (Donehower et al., 1992) mutant mice were mated and genotyped as described. Mice were checked twice a week for the development of tumors. Those that exhibited breathing difficulty, a sign of thoracic congestion because of enlarged thymus, were killed within 1 day of detection. Complete autopsies were performed for both gross and microscopic evaluations. Immunohistochemistry was performed on tumor sections using CD3 (Dako) and B220 antibodies (Pharmingen). For apoptosis assay on thymus, mice were either untreated or irradiated with a 20 gray (Gy) of g-irradiation and killed after 6-8 h. Thymus sections were analysed for apoptosis using ApoTag kit as recommended by the manufacturer (Intergen). To evaluate cells proliferation in thymus and spleen, we used the cell proliferation kit as recommended by the manufacturer (Amersham).
Flow cytometry
Thymocytes and splenocytes were stained with antibodies to CD4, CD8, Thy1, TCRb and B220 (all purchased from BD Phamingen). FACS analysis was performed using a FACSan (BD Phamingen) and data were analysed using 'FlowJo' from Tree Star.
Southern and Northern blots
Genomic DNAs were isolated from thymus tumors and lymphoma cell lines that were at passages between 3 and 5.
About 30 mg of genomic DNA digested with EcoRI restriction enzyme was electrophoresed on a 0.7% agarose gel and transferred to a Protran nitrocellulose membrane (Schleicher and Schuell). The filter was then hybridized with a 32 P-labeled p53 cDNA probe (Brodie et al., 2001a) to detect the p53 gene. RNA was isolated from thymus and spleen of mutant and control mice using RNA Tet-60 based on the protocol recommended by the manufacturer (Tel-Test 'B,' Inc.). About 20 mg of total RNA from each samples was electrophoresed on a 1% agarose gel and transferred to a Gene-Screen filter followed by hybridizing with a Brca1 probe that detects both Brca1-full-length and Brca1-D11 isoforms (Xu et al., 1999b) .
Preparation of metaphase chromosomes and Q-FISH staining
Lymphoma cell lines were established from primary tumors of thymic origin by scraping thymus between two slides and releasing thymocytes in 1 Â PBS. Cells were grown in DMEM supplemented with 10% fetal bovine serum, penicillin/streptomycin, l-glutamin, nonessential amino acids and b-mercaptoethanol. Metaphase chromosomes were prepared from early passages (passages 3-5) as previously described (Brodie et al., 2001b) . Q-FISH was performed using the Telomere PNA FISH kit (DAKO).
